Health Care • Biotechnology: Pharmaceutical Preparations
$0.53 ▼ -0.05
(-8.20%)
MKT CAP: $49.2M • VOL: 195.1K
52W L $0 52W H $2
ROARABLE / RQD
E • 34/100
PIOTROSKI
1 / 9
CTOR // SEC EDGAR XBRL STANDARDIZED FINANCIAL STATEMENTS (FA <GO>)
| LINE ITEM (USD / %) | FY 2025
FILED 2025-09-30 | FY 2024
FILED 2024-09-30 | FY 2023
FILED 2023-12-31 |
|---|---|---|---|
| Revenue (Total Sales) | $0 | $0 | $0 |
| YoY Revenue Growth % | — | — | — |
| Gross Profit | — | — | — |
| Gross Margin % | — | — | — |
| Research & Development (R&D) | — | — | — |
| Operating Income (EBIT) | -$23.5M | -$20.6M | -$1.0M |
| Operating Margin % | — | — | — |
| Net Income (GAAP) | -$24.8M | -$21.1M | $2.4M |
| EBITDA (Normalized) | — | — | — |
| Diluted EPS ($/sh) | — | — | — |
| Operating Cash Flow (OCF) | -$5.5M | $126.4K | -$601.3K |
| Capital Expenditures (CapEx) | — | — | — |
| Free Cash Flow (FCF) | -$5.5M | $126.4K | -$601.3K |
| FCF Margin % | — | — | — |
| Return on Invested Capital (ROIC %) | -36.4% | -39.4% | — |
| Cash & Short-Term Equivalents | $7.3M | — | — |
| Total Debt (Short + Long Term) | — | — | — |
| Total Stockholders' Equity | $58.4M | $41.3M | — |
NO QUARTERLY 10-Q XBRL STATEMENTS AVAILABLE IN CURRENT CACHE FOR CTOR.